|
|
||||||||
Ann Thorac Surg 1996;62:1134-1140
© 1996 The Society of Thoracic Surgeons
Departments of Cardiothoracic Surgery, Anesthesiology, and Clinical Chemistry, Ullevål University Hospital, Oslo, Norway
Accepted for publication May 14, 1996.
Background. Centrifugal pumps are being used increasingly for short-term extracorporeal circulation purposes such as during heart operations. Whether the centrifugal pump improves the cardiopulmonary bypass biocompatibility has not been fully documented.
Methods. A roller pump (n = 20) was compared in vivo with a centrifugal pump (n = 20) in groups of patients in which cardiopulmonary bypass circuits that were either totally heparin coated (Carmeda BioActive Surface; n = 20) or uncoated (n = 20) were used. We expected the heparin coating to attenuate blood activation, thus possibly making the comparison of the two pumps easier with respect to their different blood activation potentials. Samples of blood plasma, obtained during cardiopulmonary bypass from low-risk coronary artery bypass grafting patients, were analyzed for hemolysis (plasma hemoglobin), complement activation (C3bc and the terminal complement complex), a complement lytic inhibitor (vitronectin), coagulation activation (fibrinopeptide A), granulocyte activation (lactoferrin), and platelet activation (ß-thromboglobulin).
Results. The concentrations of terminal complement complex, lactoferrin, and ß-thromboglobulin were significantly lower in association with heparin-coated surfaces. The concentration of plasma hemoglobin was significantly lower in association with the centrifugal pump. In uncoated circuits, the ß-thromboglobulin level was significantly higher in association with the roller pump than with the centrifugal pump, but this significant reduction in the ß-thromboglobulin level did not hold true for the heparin-coated circuit group.
Conclusions. A heparin-coated cardiopulmonary bypass surface reduces the blood activation potential during cardiopulmonary bypass, and the centrifugal pump causes less hemolysis than the roller pump.
This article has been cited by other articles:
![]() |
S. Gunaydin, T. Sari, K. McCusker, U. Schonrock, and Y. Zorlutuna Clinical evaluation of minimized extracorporeal circulation in high-risk coronary revascularization: impact on air handling, inflammation, hemodilution and myocardial function Perfusion, May 1, 2009; 24(3): 153 - 162. [Abstract] [PDF] |
||||
![]() |
G. S. Murphy, E. A. Hessel II, and R. C. Groom Optimal Perfusion During Cardiopulmonary Bypass: An Evidence-Based Approach Anesth. Analg., May 1, 2009; 108(5): 1394 - 1417. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1058 - 1069. [Abstract] [Full Text] [PDF] |
||||
![]() |
C R Valeri, H Macgregor, G Ragno, N Healey, J Fonger, and S F Khuri Effects of centrifugal and roller pumps on survival of autologous red cells in cardiopulmonary bypass surgery Perfusion, September 1, 2006; 21(5): 291 - 296. [Abstract] [PDF] |
||||
![]() |
C. W. Hogue Jr, C. A. Palin, and J. E. Arrowsmith Cardiopulmonary bypass management and neurologic outcomes: an evidence-based appraisal of current practices. Anesth. Analg., July 1, 2006; 103(1): 21 - 37. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Asante-Siaw, J. Tyrrell, A. Hoschtitzky, and J. Dunning Does the use of a centrifugal pump offer any additional benefit for patients having open heart surgery? Interactive CardioVascular and Thoracic Surgery, April 1, 2006; 5(2): 128 - 134. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jeppsson Reply Ann. Thorac. Surg., February 1, 2006; 81(2): 791 - 791. [Full Text] [PDF] |
||||
![]() |
C. Baufreton More Biocompatibility in Cardiopulmonary Bypass for High-Risk Patients Ann. Thorac. Surg., February 1, 2006; 81(2): 790 - 791. [Full Text] [PDF] |
||||
![]() |
G. Nollert, I. Schwabenland, D. Maktav, F. Kur, F. Christ, P. Fraunberger, B. Reichart, and C. Vicol Miniaturized Cardiopulmonary Bypass in Coronary Artery Bypass Surgery: Marginal Impact on Inflammation and Coagulation but Loss of Safety Margins Ann. Thorac. Surg., December 1, 2005; 80(6): 2326 - 2332. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lindholm, M. Westerberg, A. Bengtsson, R. Ekroth, E. Jensen, and A. Jeppsson A Closed Perfusion System With Heparin Coating and Centrifugal Pump Improves Cardiopulmonary Bypass Biocompatibility in Elderly Patients Ann. Thorac. Surg., December 1, 2004; 78(6): 2131 - 2138. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Purohit Malaria and Open Heart Surgery Asian Cardiovasc Thorac Ann, September 1, 2003; 11(3): 277 - 278. [Full Text] |
||||
![]() |
G. M. Palatianos, C. N. Foroulis, M. I. Vassili, G. Astras, K. Triantafillou, E. Papadakis, A. A. Lidoriki, E. Iliopoulou, and E. N. Melissari A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit Ann. Thorac. Surg., July 1, 2003; 76(1): 129 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Scholz, R. Solberg, C. Okkenhaug, V. Videm, M. J Gallimore, O. Mathisen, T. E Mollnes, A. Bergan, O. Soreide, G. B Klintmalm, et al. The significance of heparin-coated veno-venous bypass circuits in liver transplantation Perfusion, January 1, 2002; 17(1): 45 - 50. [Abstract] [PDF] |
||||
![]() |
K. Kottke-Marchant and S. Sapatnekar Hemostatic Abnormalities in Cardiopulmonary Bypass: Pathophysiologic and Transfusion Considerations Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 187 - 206. [Abstract] [PDF] |
||||
![]() |
H. A. Hennein Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255. [Abstract] [PDF] |
||||
![]() |
D. A Palanzo, D. L Zarro, N. J Manley, R. M Montesano, M. Quinn, B.-A. Elmore, P. A Gustafson, and J. M Castagna Effect of Carmeda(R) BioActive Surface coating versus TrilliumTM Biopassive Surface coating of the oxygenator on circulating platelet count drop during cardiopulmonary bypass Perfusion, July 1, 2001; 16(4): 279 - 283. [Abstract] [PDF] |
||||
![]() |
A. Parolari, F. Alamanni, M. Naliato, R. Spirito, V. Franze, G. Pompilio, M. Agrifoglio, and P. Biglioli Adult cardiac surgery outcomes: role of the pump type Eur. J. Cardiothorac. Surg., November 1, 2000; 18(5): 575 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Miyaji, R. L. Hannan, J. W. Ojito, J. A. White, and R. P. Burke The Ross operation in a Jehovah’s Witness: a paradigm for heart surgery in children without transfusion Ann. Thorac. Surg., March 1, 2000; 69(3): 935 - 937. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. Wendel and G. Ziemer Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation Eur. J. Cardiothorac. Surg., September 1, 1999; 16(3): 342 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Baufreton, L. Intrator, P. G.M. Jansen, H. te Velthuis, P. Le Besnerais, A. Vonk, J.-P. Farcet, C. R.H. Wildevuur, and D. Y. Loisance Inflammatory response to cardiopulmonary bypass using roller or centrifugal pumps Ann. Thorac. Surg., April 1, 1999; 67(4): 972 - 977. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Weerasinghe and K. M. Taylor The platelet in cardiopulmonary bypass Ann. Thorac. Surg., December 1, 1998; 66(6): 2145 - 2152. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |